# 2026-13096: FDA to Review Heart Cell Therapy From Capricor

2026-13096, Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-29, effective 2026-07-29 (as of 2026-07-06).

- Canonical: https://policyrisk.com/federal-register/2026-13096
- As of: 2026-07-06
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13096
- Title: Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 39101
- Published: 2026-06-29
- Effective: 2026-07-29
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-07-06

## In one line

FDA to Review Heart Cell Therapy From Capricor

## Summary

The FDA is holding a public meeting on July 29, 2026, to review a new medicine called Deramiocel from Capricor, Inc., which uses special heart cells to help patients. They want your thoughts before making a decision, so anyone interested can send comments by July 28. This could change how certain heart conditions are treated and might impact patients and healthcare costs.

## Abstract

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-13096 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/29/2026-13096/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public)
- [2026-13096 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-29/pdf/2026-13096.pdf)

## Related
- [Previous: 2026-13095, Notice of Public Comments on Section 133 of the Expanding Public Lands Outdoor…](https://policyrisk.com/federal-register/2026-13095)
- [Next: 2026-13115, Sunshine Act Meetings](https://policyrisk.com/federal-register/2026-13115)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13096 (as of 2026-07-06).
